Prothena Corporation plc — Form 10-Q Summary
Business Context and Reporting Period
Prothena is an Ireland-incorporated, clinical-stage biotechnology company developing monoclonal antibodies for diseases involving protein misfolding or cell adhesion. The filing covers the three and six months ended June 30, 2013, compared with the corresponding 2012 periods.
The company separated from Elan on December 20, 2012. The 2012 comparative financial statements are presented on a carve-out basis and include allocations of Elan centralized support costs; therefore, comparisons with 2013 are not fully comparable to standalone results.
NEOD001 entered a Phase 1 clinical trial in April 2013 for AL amyloidosis. Management expected to initiate Phase 1 trials for PRX002 in 2014 and PRX003 in 2015.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2013 | Six Months Ended June 30, 2013 | Comparable Prior Period |
|---|---|---|---|
| Related-party revenue | $0.2 million | $0.3 million | $0.7 million and $1.1 million, respectively |
| Research and development expense | $8.1 million | $14.1 million | $8.0 million and $16.8 million, respectively |
| General and administrative expense | $3.2 million | $6.4 million | $2.4 million and $4.9 million, respectively |
| Total operating expenses | $11.4 million | $20.5 million | $10.4 million and $21.7 million, respectively |
| Operating loss | $11.2 million | $20.2 million | $9.7 million and $20.5 million, respectively |
| Net loss | $11.3 million | $20.3 million | $9.7 million and $20.5 million, respectively |
| Basic and diluted loss per share | $0.64 | $1.15 | $0.67 and $1.42, respectively |
| Net cash used in operating activities | Not provided for the quarter | $12.0 million | $19.0 million |
Revenue consisted entirely of fees for research and development services provided to Elan. The company had no significant third-party external revenue and remained loss-making; meaningful gross or operating margins were not reported.
At June 30, 2013, cash and cash equivalents were $112.5 million, down from $124.9 million at December 31, 2012. Total assets were $117.9 million and total liabilities were $10.7 million. The filing does not report interest-bearing debt. Shareholders’ equity was $107.2 million and accumulated deficit was $20.6 million.
Cash equivalents included $91.6 million in money market funds. Capital expenditures were $0.3 million for the six months. Share-based compensation expense was $1.1 million for the six months, with approximately $6.4 million of unearned expense expected to be recognized through 2017.
Material Changes Versus the Prior Comparable Period
- Second-quarter revenue declined 77% to $0.2 million, and six-month revenue declined 70% to $0.3 million, primarily because the scope of R&D services provided to Elan was reduced.
- Second-quarter R&D expense increased 2% to $8.1 million, while six-month R&D expense decreased 16% to $14.1 million. The six-month decrease was primarily attributed to lower share-based compensation, personnel costs and NEOD001 external costs, partly offset by higher PRX002 and PRX003 costs.
- General and administrative expense increased 32% for the quarter and 31% for the six-month period, reflecting professional services, internal personnel costs and the costs of operating as a standalone public company.
- Second-quarter net loss increased 16% to $11.3 million, while the six-month net loss decreased slightly by 1% to $20.3 million.
- Operating cash burn improved to $12.0 million from $19.0 million in the prior-year six-month period, primarily because of higher current liabilities and working-capital changes.
- The company had $17.7 million ordinary shares outstanding at June 30, 2013, compared with a weighted-average of $14.5 million shares in the 2012 comparative periods.
Guidance, Outlook, Risks and Unusual Items
Management believed that cash and cash equivalents at June 30, 2013 would fund obligations for at least the next twelve months under its current business plan. Management also stated that substantial additional capital will be required to continue development and obtain regulatory approval for its product candidates.
The company cannot reliably estimate the timing or total cost of completing the NEOD001 Phase 1 trial or future development programs. Additional financing may be obtained through equity or debt offerings, collaborations, licensing arrangements or other transactions, but availability and terms are uncertain and equity financing could dilute shareholders.
Key risks include clinical-trial failure or delay, regulatory uncertainty, inability to commercialize candidates, competition, intellectual-property challenges, dependence on key personnel and collaborators, limited external revenue, continued operating losses, and the possibility that cash resources could be used sooner than expected.
All reported revenue was from Elan, creating customer and related-party concentration. The Transitional Services Agreement with Elan was expected to remain in effect no later than December 31, 2013. No material legal proceedings or off-balance-sheet arrangements were reported. Management concluded that disclosure controls were effective as of June 30, 2013.
Important Facts for Investors to Verify
- Progress, safety results, enrollment and costs of the NEOD001 Phase 1 trial.
- Timing and clinical readiness of PRX002 and PRX003.
- Cash burn relative to the $112.5 million cash balance and the timing of future financing needs.
- Future revenue dependence on Elan and the terms, duration and renewal or termination of related-party agreements.
- Comparability of 2013 results with 2012, given the 2012 carve-out presentation and Elan cost allocations.
- Potential dilution, debt obligations or loss of strategic rights if additional capital is raised.
- Unrecognized share-based compensation of approximately $6.4 million and its future effect on reported expenses.